ClinicalTrials.gg
CompletedNCT00720018NP101-006Updated Feb 3, 2016

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers

A Phase 1 interventional study of NP101 Sumatriptan Iontophoretic Transdermal Patch in Migraine Disorders, sponsored by NuPathe Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-03.

Sponsored by NuPathe Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. — none open to participants now, none under way, none of them phase 3. Migraine Disorders · Teva Pharmaceutical Industries, Ltd..

Enrollment
19th of 19
4 · median 353
Started
2008
with 1 other
Phase 1
3 of 20
none open now
Registered
2nd of 20
by date

Among the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd., this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Migraine Disorders, anywhere →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Migraine Disorders by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers.

The secondary objective is to evaluate the safety of NP101 in healthy volunteers.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Caucasian men or women aged 18 to 45.
  • Subjects have of 18 to 30 kg/m2 inclusive.
  • Subject judged to be in good health, based upon the results of a medical history, physical examination, vital signs, and laboratory profile. Subjects will not have any abnormal findings in order to qualify for enrollment.
  • Subject must have a negative drug screen at screening and on Day -1 for all treatment.
  • Subjects must be nonsmokers, defined as having not used any tobacco products in the 6 months before screening.
  • The subjects will have received no other medication except , for two weeks prior to study entry.
  • Subjects must have not consumed alcoholic beverages, poppy seeds, grapefruit, and/or grapefruit juice within 72 hours prior to admission.
  • Female of must have a negative pregnancy test at screening and on Day -1 for all treatment.
  • In the investigator's opinion, the subject must be likely to complete the study.
  • Subjects must be able to communicate effectively and be capable of reading and understanding English and voluntarily sign an IRB approved IC agreement.

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of allergy or to any component of the study patch used in this study.
  • Subject has any generalized skin irritation or disease including eczema, psoriasis, melanoma, contact dermatitis or acne.
  • Subject has a tattoo that might interfere with skin irritation examination.
  • Subject has a history of epilepsy or conditions associated with a lowered seizure threshold.
  • Subject has a history of basilar or hemiplegic migraines.
  • Subject has suspected or confirmed cardiovascular disease that contraindicates participation.
  • Subject has Raynaud's disease.
  • Subject has a history (within 1 year) or current evidence of drug or alcohol abuse or dependence.
  • Subject with a history of within the past 5 years.
  • Subject has abnormal laboratory parameters, vital signs or parameters.
  • Subject has /AST, SGPT/ALT, alkaline phosphatase or total ≥ 1.5 times the .
  • Subject with a (Hgb) level of less than 7.5 mmol/L.
  • Subject is , or positive.
  • Subject has taken an MAO inhibitor, preparations containing St. John's Wort, SSRI, SNRI, TCA, triptan or ergot medication, within one month prior to screening.
  • Subject is unwilling to discontinue the use of phosphodiesterase type 5 inhibitor, from screening through the End of Study.
  • Subject who has been administered an injectable drug, except for local anesthetic or , within 30 days prior to the initial study drug administration.
  • Donation of blood or blood products within 8 weeks prior to study entry.
  • Receipt of an drug or participation in any clinical study within 90 days prior to study.
  • Subject who requires any medication on a regular basis, with the exception of steroidal contraceptives.
  • Concurrent use of Rx or OTC medications or natural medicine (herbal) products, with the exception of steroidal contraceptives.
  • Female subject who is pregnant, planning a pregnancy during the study, breast feeding; or if of , not using or unwilling to use an effective form of contraception during the study and for a period of 30 days following dosing.
  • Subject who is considered to be an unsuitable candidate for receiving sumatriptan, or as being unsuitable for any other reason.
  • Subject is electrically sensitive (e.g., prior iontophoresis with adverse outcome related to the current delivered by the device) or who have an implantable electronic device (e.g., pacemaker).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Period 1

    NP101 Patch

    Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch

  • Experimental
    Period 2

    NP101 Patch

    Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch

  • Experimental
    Period 3

    NP101 Patch

    Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch

  • Experimental
    Period 4

    NP101 Patch

    Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch

  • Experimental
    Period 5

    NP101 Patch

    Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective was to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers.

    Time frame: Blood samples were collected at time points: pre-dose (within 15 minutes prior to dosing) and at 0.25, 0.50, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 16 hrs post-dose.

07

Study locations

1 site
  • Prism Research
    St. Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2008
First posted
Jul 22, 2008
Start
Jun 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Feb 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00720018
Lead sponsor
NuPathe Inc.
Responsible party
Sponsor
First posted
Jul 22, 2008
Start date
Jun 2008
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Feb 3, 2016

Study contacts

Shannon M Canas, MD
principal investigator · Prism Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement · Sumatriptan

Start the discussion